Curran Walter J
Department of Radiation Oncology, Jefferson Medical College, Philadelphia, Pa. 19107-5097, USA.
Oncology. 2002;63 Suppl 2:29-38. doi: 10.1159/000067145.
The institution of combined modality therapy for unresected solid tumors has resulted in significant improvements in tumor control and survival benefit compared with radiotherapy (RT) alone. A number of chemotherapy agents that can enhance the effectiveness of RT, such as cisplatin and 5-fluorouracil, are now considered standard treatment for patients with a number of cancer types. There is growing interest in a number of additional agents that have also been found to have radiosensitizing ability. These include paclitaxel, docetaxel, irinotecan, gemcitabine, and vinorelbine, as well as biologic agents. Other agents may be of value because they act to counter dose-limiting toxicities associated with RT. This article provides an update of some important, recently completed and ongoing clinical trials evaluating novel chemoradiation protocols, with examples taken primarily from studies conducted by the Radiation Therapy Oncology Group (RTOG). Theoretical approaches to the development of new agents and combined modality regimens are also discussed.
与单纯放疗（RT）相比，对无法切除的实体瘤采用联合治疗模式已在肿瘤控制和生存获益方面取得了显著改善。一些能够增强放疗效果的化疗药物，如顺铂和5-氟尿嘧啶，现在被认为是多种癌症类型患者的标准治疗方法。人们对其他一些也被发现具有放射增敏能力的药物的兴趣与日俱增。这些药物包括紫杉醇、多西他赛、伊立替康、吉西他滨和长春瑞滨，以及生物制剂。其他药物可能有价值，因为它们可对抗与放疗相关的剂量限制性毒性。本文提供了一些重要的、近期完成和正在进行的评估新型放化疗方案的临床试验的最新情况，主要以放射治疗肿瘤学组（RTOG）开展的研究为例。还讨论了开发新药物和联合治疗方案的理论方法。
